David J. Woodhouse - 02 Mar 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC

Role: Chief Executive Officer, Director
Signature: /s/ Valerie Pierce, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 02 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 06 Mar 2023, 16:09:32 UTC
Previous filing: 09 Jun 2022
Next filing: 19 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGM	Common Stock	Award	$0	+127,200	+721%	$0.000000	144,854	02 Mar 2023	Direct	F1
holding	NGM	Common Stock						80,000	02 Mar 2023	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NGM	Stock Option (Right to Buy)	Award	$0	+381,600		$0.000000	381,600	02 Mar 2023	Common Stock	381,600	$4.36	Direct	F3
transaction	NGM	Stock Option (Right to Buy)	Award	$0	+500,000		$0.000000	500,000	02 Mar 2023	Common Stock	500,000	$4.36	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
F2	Shares held by The Woodhouse Family Trust 9/8/05.
F3	The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
F4	1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.